Based on the Zydus Lifesciences Limited stock forecast from 5 analysts, the average analyst target price for Zydus Lifesciences Limited is INR 887.14 over the next 12 months. Zydus Lifesciences Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Zydus Lifesciences Limited is Neutral, which is based on 6 positive signals and 6 negative signals. At the last closing, Zydus Lifesciences Limited’s stock price was INR 937.00. Zydus Lifesciences Limited’s stock price has changed by -5.75% over the past week, -5.47% over the past month and +81.62% over the last year.
No recent analyst target price found for Zydus Lifesciences Limited
No recent average analyst rating found for Zydus Lifesciences Limited
Company Overview Zydus Lifesciences Limited
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company offers the products under the Everyuth and Nutralite, Complan, Glucon D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Read Less
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through Pharmaceuticals and Consumer Products segments. It offers finished dosag...Read More
Frequently Asked Questions About Zydus Lifesciences Limited (ZYDUSLIFE:NSE) Stock
Based on ratings from 5 analysts Zydus Lifesciences Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 6 buy, sell and 1 hold ratings.
ZYDUSLIFE:NSE stock's dividend yield is 0.60%.
Our analysis grades ZYDUSLIFE:NSE stock's dividend yield at F. This means that ZYDUSLIFE:NSE stock's dividend yield is above 52% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this ZYDUSLIFE:NSE may be a average dividend stock for its sector.
Based on targets from 5 analysts, the average taret price for ZYDUSLIFE:NSE is INR 887.14 over the next 12 months. The maximum analyst target price is INR 1100 while the minimum anlayst target price is INR 696.
ZYDUSLIFE:NSE stock's Price/Earning ratio is 34.48.
Our analysis grades ZYDUSLIFE:NSE stock's Price / Earning ratio at F. This means that ZYDUSLIFE:NSE stock's Price/Earning ratio is above 47% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this ZYDUSLIFE:NSE may be fairly valued for its sector
The last closing price of ZYDUSLIFE:NSE's stock was INR 937.00.
The most recent market capitalization for ZYDUSLIFE:NSE is INR 1,012.77B.
Based on targets from 5 analysts, the average taret price for ZYDUSLIFE:NSE is projected at INR 887.14 over the next 12 months.
This means that ZYDUSLIFE:NSE's stock price may go down by -5.32% over the next 12 months.
We can't find any ETFs which contains Zydus Lifesciences Limited's stock.
As per our most recent records Zydus Lifesciences Limited has 23,026 Employees.
Zydus Lifesciences Limited's registered address is Zydus Corporate Park, Ahmedabad, India, 382481.
You can get more information about it from Zydus Lifesciences Limited's website at https://www.zyduslife.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ZYDUSLIFE:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
